Cipla and Stempeutics collaborate for Stempeucel, to treat Critical Limb Ischemia (CLI)

▴ cipla-and-stempeutics-collaborate-to-treat-critical-limb-ischemia-cli
First approved allogeneic cell therapy product globally for the treatment of CLI

Cipla Limited referred to as "Cipla" today announced that its partner Stempeutics Research Pvt. Ltd has received regulatory approval by the Drug Controller General of India (DCGI) for the launch of Stempeucel in India. The product is indicated for the treatment of CLI due to Buerger's Disease and Atherosclerotic Peripheral Arterial Disease. It is the first allogeneic cell therapy product to be approved for commercial use in India and the first stem cell product to be approved globally for CLI treatment.

The product has been developed by Stempeutics over a period of twelve years. The company's proprietary pooling approach provides for an efficient manufacturing process thereby enabling the product to be made accessible to patients at an affordable cost. More than one million doses can be produced from a single set of master cell banks, which is unique in regenerative medicine, thus providing consistent product to patients. The proprietary technology also helps Stempeucel extend the therapeutic potential of the drug across multiple disease categories. Under the agreement signed between the two companies, Cipla has received exclusive rights to market and distribute the product in India by leveraging its expansive distribution strengths across the country.

CLI is a progressive form of peripheral arterial disease that is caused by severe blockage in the arteries thereby reducing blood flow. This may result in the development of sores and wounds in legs and feet with a high risk of limb amputation. It is estimated that about 5 million patients in India are impacted by this debilitating disease. With the current contemporary vascular techniques, it is estimated only 25% of patients can be managed with satisfactory clinical outcomes.

Stempeucel is a breakthrough treatment which is designed to enhance the body's limited capability to restore blood flow in ischemic tissue. It is derived from allogeneic pooled mesenchymal stromal cells isolated from the bone marrow of healthy, adult voluntary donors. It directly addresses the root cause of the disease by reducing inflammation, stimulating growth of collateral blood vessels and repairing damaged muscle, thereby reducing the pain, healing the ulcers and salvaging the affected limb. The drug is administered through intramuscular injections around the calf muscle region and around the site of ulcers.

Currently, Stempeutics is working on a strategy for other international markets including US, EU and Japan. The global critical limb ischemia treatment market expected to generate USD 5,390 million by 2025, at a CAGR of 8.1% between 2020 and 2025.

Commenting on the DCGI approval, Mr. Manohar BN, MD & CEO of Stempeutics, said, "Obtaining DCGI approval for Stempeucel is an important and historic milestone for Stempeutics. It is a strong recognition for Stempeutics for its sustained excellence of scientific and clinical work and underscores our global leadership in allogeneic, pooled MSC technology. We believe that the Stempeucel product is a game-changer, offering an advanced therapeutic treatment for millions of patients suffering from this dreadful disease."

Mr. Umang Vohra, Managing Director and Global CEO of Cipla, said, "Our focus on innovation is guided by our strong sense of responsibility to address unmet patient needs and alleviate suffering. We are pleased to see that our decade-long partnership with Stempeutics has achieved a significant milestone. CLI is a serious and painful condition that impacts patients worldwide and we are happy that we are able to introduce this stem cell therapy in the country at an affordable cost."

Dr Pawan Kumar Gupta, Senior VP, Medical & Regulatory Affairs, Stempeutics, said, "We are excited to receive this marketing approval from DCGI for this very important indication. In CLI, fatty deposits block arteries in the leg, leading to greatly reduced blood flow, pain at rest, non-healing ulcers, and gangrene. Patients with CLI are at an immediate risk for limb amputation and death. Now Stempeucel® provides hope for a new, effective treatment and a better quality of life for such CLI patients. Also, Stempeutics is committed to advancing its peripheral artery disease programs in CLI to other parts of the World."

Tags : #CIPLA #Stempeutics #BreakthroughinCli #CriticalLimbIschemia #LatestPharmaUpdateAug21 #LatestPharmaNewsAug21

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

India Joins International Medical Device Regulators Forum: A Leap Toward Global Health CollaborationOctober 05, 2024
The Science of Overeating: Why You Can’t Stop at Just One BiteOctober 05, 2024
The Toxic Truth: How Alcohol Fuels Six Deadly CancersOctober 05, 2024
Lenacapavir: India’s Pharmaceutical Giants to Produce a Twice-a-Year Pill Poised to Rewrite HIV PreventionOctober 04, 2024
Can Ending Smoking by 2050 Really Save 1.2 Million Lives? New Lancet Study RevealsOctober 04, 2024
Colon Cancer Crisis: Why It’s Attacking Younger GenerationsOctober 04, 2024
Eye Health Program for Low-Income Residents Launched in Hingoli, MaharashtraOctober 04, 2024
Are we on the path to end AIDS by 2030?October 03, 2024
TTK Prestige Announces Shubhutsav- A Special Festive Offer, Elevating Home CookingOctober 03, 2024
Tata Soulfull Launches Tata Soulfull Corn Flakes+, With the Goodness of Millets in Every Flake October 03, 2024
The Bitter Truth Behind Sweet Treats: Hidden Cancer Risks in Your Favorite CakesOctober 03, 2024
Ageing Faster Than You Think? Discover How a Simple Cheek Swab Could Save Your LifeOctober 03, 2024
The University of Tasmania invites international student applications for their Tasmanian International ScholarshipOctober 03, 2024
A New Hope for Type 1 Diabetes: Tackling Blood Sugar Drops with Somatostatin BlockersOctober 03, 2024
Prostate Cancer Strikes Young: The Alarming Rise of Aggressive Cases in Men Under 50October 03, 2024
Fleetguard Filters Private Limited (FFPL) Wins Prestigious ‘Iconic Brands of India 2024’ at the This recognition adds to Fleetguard's growing list of accolades, further establishing its position as a leader in the automotive industry. The company remains dedicated to advancing innovation and providing solutions that consistently meet the changing needs of its customers.October 03, 2024
Marico’s Saffola Honey and Pankaj Tripathi Uncover the Secret of Shuddha Honey in its latest TVCOctober 01, 2024
Mr. Piush Srivastava, Head of Marketing and Corporate Communications of Fleetguard Filters Pvt. Ltd, Awarded 'Marketing Maverick' by Dun & Bradstreet October 01, 2024
Chikungunya Strikes Back: The Forgotten Virus Making a Deadly ComebackOctober 01, 2024
The Hidden Cancer Risk in Your Morning Routine: How Poor Oral Hygiene May Be Endangering Your HealthOctober 01, 2024